LION bioscience Provides Incyte with SRS Integration Power for Better Genomics Analysis and Faster Drug Discovery
HEIDELBERG, Germany, CAMBRIDGE, Mass. & PALO ALTO, Calif--(BW HealthWire)--April 02, 2002--
LION bioscience (Nasdaq: LEON), a leading provider of integrated IT solutions for the life sciences industry, announced today that Incyte Genomics, Inc. (Nasdaq: INCY - news), a leading genomics information company, has chosen to license LION's SRS integration platform, which both companies believe will enable Incyte's customers to optimize data access and analysis for faster research and development.
Incyte Genomics, which has the largest commercial portfolio of U.S. patents for genomic data and a client base that includes many of the world's leading pharmaceutical companies, has signed a three-year agreement with LION. Under the terms of the agreement, LION will develop a customized application powered by SRS technology that gives Incyte customers a user-friendly web-based interface to access and analyze the wealth of genomic and proteomic data and technology that Incyte provides through its information product offerings. By leveraging the SRS integration platform, Incyte customers will have the opportunity, through LION, to integrate Incyte information with data from other relevant sources. As the flood of genomics and proteomics information grows, so do researchers' needs for powerful software tools for integrating and analyzing diverse data quickly and accurately in order to transform that information into answers to disease.
The collaboration takes both companies to the next level of operational excellence by providing Incyte customers with an extensible software solution that enables data integration and by giving LION another opportunity to showcase the enhanced integration possibilities of LION's SRS technology across diverse databases to Incyte's broad customer base of large pharmaceutical and biotechnology companies.
Although financial terms were not disclosed, LION will receive annual license fees and royalties for the portal from Incyte as well as for each of Incyte's customers that uses the SRS-based software platform to work with Incyte data on its Intranet.
``We are pleased to offer our customers LION's powerful functionality to access, view and analyze our LifeSeq data,'' said Mike Lack, Chief Operating Officer for Incyte. ``Many of our LifeSeq collaborators already use SRS in-house. Those collaborators should recognize immediate benefits from this relationship since they will now be able to integrate LifeSeq Foundation information and visualization capabilities with other sources of data directly through their existing SRS installation. This improved access to and analysis of our information will be an asset for developing new products, and we therefore expect the synergies of our collaboration with LION to result in a higher demand for our genomics technologies.''
``We are delighted to have the opportunity to provide the interface to the rich and comprehensive genomic, transcriptomic and proteomic information provided in the LifeSeq Foundation Database,'' said Dr. Daniel Keesman, Executive Vice President Global Business of LION bioscience. ``This partnership with Incyte underscores the position of LION's SRS technology as the industry standard for providing the most flexible, comprehensive and user-friendly integration solutions for content providers in the life sciences as well as in the pharmaceutical industry. LION's IT solutions allow companies to focus on their core competencies and capitalize on their IT investments by delivering content in the broadest and most efficient way and developing new products faster.''
The combination of LION's customized SRS integration platform and Incyte's content will enable Incyte's customers to quickly and easily query, navigate and explore Incyte's genomic data. The offering will be available as a portal to provide online access to the Incyte LifeSeq database or for installation at a customer-specific site. The customized application leveraging the SRS integration platform will connect Incyte data with the most important public biological databases. Customers may also upgrade to a full SRS integration license with LION that will enable them to integrate their own proprietary data with publicly available data from the hundreds of sources available to SRS within their own firewall and provide them with more powerful analysis and visualization capabilities.
About SRS
LION's SRS platform is a leading integration technology with connections to more than 500 databases, representing the vast majority of public databases. LION has established SRS as the industry standard for life sciences research by licensing SRS to more than 60 leading life science companies and more than 130 academic institutions. LION has also provided the most important and most prominent portals in the life sciences industry, all based on SRS: full genomic data for humans, mice and fruit flies from Celera Genomics; microarray data from Affymetrix; scientific literature data from The Scientific World; and patent information from Derwent.
About LifeSeq® Foundation
LifeSeq Foundation is the result of years of research, during which Incyte created the world's largest collection of pharmaceutically relevant full-length gene transcripts that are now anchored to public genomic sequence data. LifeSeq Foundation is a comprehensive database of potential drug and therapeutic targets, annotated by Incyte's proprietary functional information and research tools. This database, built on the strengths of LifeSeq Gold, provides more than just sequence information; it delivers detailed information about gene function, providing a means for researchers to quickly begin validation experiments. In addition, LifeSeq Foundation will also include RNA expression data, genetic data in the form of single nucleotide polymorphisms (SNP) and comparative sequence information that will yield homologues with rats and mice... |
